61. 自己免疫性溶血性貧血 Autoimmune hemolytic anemia Clinical trials / Disease details


臨床試験数 : 146 薬物数 : 131 - (DrugBank : 59) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 158

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04083014
(ClinicalTrials.gov)
August 20, 201931/8/2019Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic AnemiaAn Open, One-arm, Prospective Study of a Single Dose Anti-CD20 Monoclonal Antibody Combined With Bortezomib for Treatment of Relapsed Refractory Autoimmune Hemolytic AnemiaAutoimmune Hemolytic Anemia;Autoimmune Hemolytic Anemia and Autoimmune ThrombocytopeniaDrug: combination of a single dose anti-CD20 antibody and bortezomibPeking Union Medical College HospitalNULLRecruiting18 Years80 YearsAll43Phase 2China
2NCT01696474
(ClinicalTrials.gov)
December 201227/9/2012Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin DiseaseShort Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin DiseaseRefractory Cold Agglutinin DiseaseDrug: BortezomibGruppo Italiano Malattie EMatologiche dell'AdultoNULLCompleted18 YearsN/AAll21Phase 2Italy
3EUCTR2011-006329-42-IT
(EUCTR)
11/10/201230/10/2012Short treatment with a drug for patients affected by a type of a treatment-resistant anaemia, where the red cells are destroyed by some cold cells (autoantibodies).Short course of Bortezomib in anemic patients with refractory cold agglutinin disease Anaemia with refractory cold agglutinin disease
MedDRA version: 14.1;Level: PT;Classification code 10009868;Term: Cold type haemolytic anaemia;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: VELCADE*EV 1FL 3,5MG 1MG/MLG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTONULLNot RecruitingFemale: yes
Male: yes
25Phase 2Italy